Koppe Manuel J, Postema Ernst J, Aarts Frits, Oyen Wim J G, Bleichrodt Robert P, Boerman Otto C
Department of Surgery, Radboud University Nijmegen Medical Center, The Netherlands.
Cancer Metastasis Rev. 2005 Dec;24(4):539-67. doi: 10.1007/s10555-005-6195-z.
Radioimmunotherapy (RIT) using radiolabeled monoclonal antibodies (MAbs) directed against tumor-associated antigens has evolved from an appealing concept to one of the standard treatment options for patients with non-Hodgkin's lymphoma (NHL). Inefficient localization of radiolabeled MAbs to nonhematological cancers due to various tumor-related factors, however, has refrained RIT from outgrowing the experimental stage in solid tumors. Still, small volume or minimal residual disease has been recognized as a potentially suitable target for radiolabeled antibodies. Several strategies are being explored aimed at improving the targeting of radiolabeled MAbs to solid tumors thus improving their therapeutic efficacy. In this review, a historical overview of the application of RIT is given and various aspects of the application of radiolabeled MAbs as anti-cancer agents are discussed. Finally, the clinical results of RIT of NHL, colorectal cancer, ovarian cancer, breast cancer, and renal cell cancer are reviewed.
使用针对肿瘤相关抗原的放射性标记单克隆抗体（MAb）进行的放射免疫疗法（RIT）已从一个颇具吸引力的概念发展成为非霍奇金淋巴瘤（NHL）患者的标准治疗选择之一。然而，由于各种肿瘤相关因素，放射性标记的MAb在非血液系统癌症中的定位效率低下，这使得RIT在实体瘤中仍未超出实验阶段。尽管如此，小体积或最小残留病灶已被认为是放射性标记抗体潜在的合适靶点。目前正在探索多种策略，旨在提高放射性标记的MAb对实体瘤的靶向性，从而提高其治疗效果。在本综述中，对RIT的应用进行了历史概述，并讨论了放射性标记的MAb作为抗癌药物应用的各个方面。最后，回顾了RIT治疗NHL、结直肠癌、卵巢癌、乳腺癌和肾细胞癌的临床结果。
